<- Go Home

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Market Cap

INR 1.0T

Volume

79.9K

Cash and Equivalents

INR 13.0B

EBITDA

INR 85.6B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

INR 184.6B

Profit Margin

59.31%

52 Week High

INR 1.4K

52 Week Low

INR 1.0K

Dividend

0.67%

Price / Book Value

3.15

Price / Earnings

18.67

Price / Tangible Book Value

4.70

Enterprise Value

INR 996.0B

Enterprise Value / EBITDA

11.46

Operating Income

INR 70.5B

Return on Equity

18.47%

Return on Assets

10.32

Cash and Short Term Investments

INR 59.9B

Debt

INR 51.1B

Equity

INR 321.6B

Revenue

INR 311.3B

Unlevered FCF

INR 13.5B

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches